This post was originally published on this site
Amgen Inc. AMGN, -0.13% said it will sell the cholesterol drug Repatha only at a list price 60% lower than what the company had originally charged, in a bid to make the medicine more affordable to patients and kick-start sales.
Starting next year, Repatha will list for $5,850 a year for all insurers, the biotech said Thursday.
The move could help reduce the amount that patients pay for the drug at the pharmacy counter, and reduce the number of patients who don’t fill their prescriptions because their copays are too expensive.
Amgen had priced Repatha for more than $14,000 a year upon its approval in 2015.
A full version of this stories appears on WSJ.com
Popular stories from WSJ
